San Francisco, CA USA (UroToday.com) Hiroji Uemura and colleagues presented their single-arm, open-label, multicenter, phase II study on the use of Radium 223 in a cohort of Japanese prostate cancer patients with symptomatic bony metastases. Patients in the study had at least 2 sites of osseous metastases on nuclear scan with no evidence of visceral disease, and included patients with or without prior docetaxel treatment.
ASCO GU 2016
San Francisco, CA USA (UroToday.com) Radium-223 is approved for symptomatic bone metastasis in castrate-resistant prostate cancer and is shown to improve patient overall survival. A course of Radium-223 is an injection every 4 weeks for total 6 doses. Treatment beyond that is yet unknown and remains the subject of this international propective study.
San Francisco, CA USA (UroToday.com) Dr. Motzer from Memorial-Sloan Kettering Cancer Center (MSKCC) presented subgroup analyses from the phase III CheckMate 025 clinical trial of nivolumab versus everolimus in advanced renal cell carcinoma (RCC). This study randomized 821 patients with previously treated advanced RCC with 1-2 vascular endothelial growth factor-directed therapies to either nivolumab (3 mg/kg IV every 2 weeks), a programmed death 1 receptor
San Francisco, CA USA (UroToday.com) Dr. Escudier from Institut Gustave Roussy, Villejuif, France, presented subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced clear cell renal cell carcinoma (RCC). Cabozantinib is a multi-targeted tyrosine kinase inhibitor (TKI) with activity against vascular endothelial growth factor receptor (VEGFR), MET and AXL, the latter two of which have been associated with resistance to VEGFR TKI therapy. This open-label, phase 3 study randomized 658 patients with previously treated advanced RCC with no limit to the number of prior therapies to cabozantinib (60mg orally once daily) or everolimus (10mg orally once daily).
A pilot study was conducted to determine if bladder and bowel symptoms occurred with sufficient frequency and impact on quality of life to warrant behavioral therapy prior to, during, and after Intensity-Modulated Radiation Therapy (IMRT).
San Francisco, CA USA (UroToday.com) Dr. Katherine Nathanson of the University of Pennsylvania described inherited genetic susceptibility associated with testicular germ cell tumors. Testicular cancer is the most common cancer among white men aged 15-34 years. Over the last decade, the incidence has been rising in this population, while the incidence among black men remains low and has been relatively stable. Dr. Nathanson pointed out that all testicular cancer, both nonseminoma and seminoma, originate from a disruption in maturation of gonocytes early in development. Thus, the risk factors for developing germ cell cancers of various histologies are the same.
San Francisco, CA USA (UroToday.com) Dr. Darren Feldman of Memorial Sloan Kettering Cancer Center presented a discussion of the approach to standard treatment of high-risk germ cell tumors, with an emphasis on whether dose intensification should be used routinely. Recently reported 5-year progression free survival for men with poor risk germ cell tumor is 50-50%, demonstrating clear room for improvement for poor risk patients. Standard of care has generally been unchanged for nearly 30 years and is 4 cycles of BEP (bleomycin, etoposide, cisplatin). Williams and colleagues established this regimen when they demonstrated that